- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01372579
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Study Overview
Status
Conditions
- Male Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Triple-negative Breast Cancer
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage IIIC Breast Cancer
- Estrogen Receptor-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- HER2-negative Breast Cancer
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the pathologic complete response rate (pCR) at the time of definitive surgery.
SECONDARY OBJECTIVES:
I. Determination of the clinical response rate, as measured by clinical exam and imaging studies prior to initiation of therapy and prior to surgery.
II. Measurement of alpha B-crystalline in tissue obtained before initiation of therapy and at the time of definitive surgery.
III. Stem cell markers (cluster of differentiation [CD]44+, CD24-, CD133, aldehyde dehydrogenase 1 [ALDH1] and evaluation of the NOTCH pathway) in tissue obtained before initiation of therapy and at the time of definitive surgery.
IV. Measurement of proliferation markers (Ki67) before and after treatment in tissue obtained before imitation of therapy and at the time of definitive surgery.
V. Measurement of beta III tubulin in tissue obtained before initiation of therapy and at the time of definitive surgery.
VI. Measurement of Tau in tissue obtained before initiation of therapy and at the time of definitive surgery.
VII. Safety evaluation, including following of patients for alopecia and neuropathy.
VIII. Epidermal growth factor receptor (EGFR) staining before and after treatment in tissue obtained before initiation of therapy and at the time of definitive surgery.
OUTLINE:
Patients receive eribulin mesylate intravenously (IV) over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologically confirmed breast cancer; diagnosis must be reviewed and confirmed by the pathology department at Northwestern Memorial Hospital prior to registration on study, and all biopsy materials need to be reviewed and available for correlative studies
- Patients must have stage I-III breast cancer
- Patients must have estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), human epidermal growth factor receptor 2-negative (Her2-) (0, 1+) or fluorescent in situ hybridization (FISH) < ratio of 1.8
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) by mammogram, ultrasound or physical exam
- Prior diagnosis of cancer is allowed as long as patient is free of disease and has been off treatment for the prior malignancy for a minimal interval of one year
- Patients must have a life expectancy of > 12 weeks
- Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 80%)
- Leukocytes >= 3,000/ul
- Absolute neutrophil count >= 1,500/ul
- Platelets >= 100,000/ul
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/ alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Creatinine: within normal institutional limits
- OR creatinine clearance >= 60 mL/min/1.73^2 for patients with creatinine levels above institutional normal
- Women of childbearing potential must commit to the use of effective contraception while on study
- Eligibility of patients receiving medications of substances known to affect, or with the potential to affect, the activity or pharmacokinetics of eribulin will be determined following review of their use by the Principal Investigator
- All patients must have given signed, informed consent prior to registration on study
Exclusion Criteria:
- Prior chemotherapy, immunotherapy or hormonal therapy for breast cancer is NOT allowed
- Concomitant radiotherapy is NOT allowed
- Patients may NOT be receiving any other investigational agents or concurrent anticancer therapies; in addition, use of any herbal (alternative) medicines is NOT permitted
- Patients with uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations what would limit compliance with study requirements are NOT eligible to participate
- Women who are pregnant or lactating are NOT eligible to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (neoadjuvant chemotherapy)
Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1.
Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IV
Other Names:
Correlative studies
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the pathologic complete response rate (pCR).
Time Frame: Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measurement of alpha B-crystalline in tissue obtained
Time Frame: Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Stem cell markers (CD44+, CD24-, CD133, ALDH1 and evaluation of the NOTCH pathway) in tissue
Time Frame: Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Measurement of proliferation markers (Ki67)
Time Frame: Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Measurement of beta III tubulin in tissue
Time Frame: Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Measurement of Tau in tissue
Time Frame: Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Determination of the clinical response rate, as measured by clinical exam and imaging studies prior to initiation of therapy and prior to surgery.
Time Frame: Imaging studies at baseline and at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Imaging studies at baseline and at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Safety profile of this drug combination
Time Frame: Symptom assessment prior to each cycle (approximately every 3 weeks) and until resolution 6 months after the last dose of study treatment
|
Symptom assessment prior to each cycle (approximately every 3 weeks) and until resolution 6 months after the last dose of study treatment
|
EGFR staining before and after treatment
Time Frame: Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Biopsy at baseline and tissue removed at time of surgery (after approximately 12 weeks of neoadjuvant therapy)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Virginia Kaklamani, MD, Northwestern University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NU 10B07
- NCI-2011-00600 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- STU00045038 (Other Identifier: Northwestern University IRB#)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Breast Cancer
-
Centro Hospitalar Lisboa OcidentalInstituto Nacional de Medicina Legal e Ciências Forenses, Delegação do SulUnknownMale Breast Cancer | Female Breast Cancer
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Organon and CoInstitute for Applied Economics and Health Research ApsCompleted
Clinical Trials on carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland